Open main menu

Psychiatrienet β

Haloperidol-Risperidone LA

Revision as of 16:31, 8 February 2010 by Klaas (talk | contribs)
Haloperidol
Type Antipsychotic
Group Butyrophenones
links
ATC-code N05AD01
Medscape Haloperidol
PubChem 3559
PubMed Haloperidol
Drugs.com haloperidol
Kompas (Dutch) Haloperidol
Wikipedia Haloperidol
Risperidone
long acting
Type Antipsychotic
Group Atypical AP
links
Medscape Risperidone
PubChem 5073
PubMed Risperidone
Kompas (Dutch) Risperidone
Wikipedia Risperidone

Switch medication from Haloperidol to Risperidone_LA.[5] [6]

Nietinrijdenbord.png Stop Haloperidol
  • Day 1-14: Continue drug at usual dose
  • Day 15-18: approx. 75% of initial dose
  • Day 19-22: approx. 50% of initial dose
  • Day 23-27: approx. 25% of initial dose
  • Day 28: stop
Eenrichtingbord.png Start Risperidone_LA
  • Day 1: Start depot according general dosing advice (Dotted line in graph)
Infobord.png More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[7]
  • Alternatively, first switch to oral form and then switch to depot to manage possible (adverse) reactions. With a direct switch to a depot it is advisable to administer a low testdose in order to exclude adverse reactions.
  • Cognitive functions could improve after this switch.[8]
  1. ↑ WHO Collaborating Centre for Drug Statistics Methodology ATC=N05AD01
  2. ↑ 2.0 2.1 2.2 KNMP; Informatorium Medicamentorum 2023; Monografie "haloperidol" (Dutch)
  3. ↑ 3.0 3.1 The Lundbeck Institute; Psychotropics; Terminal Plasma Half-lives
  4. ↑ 4.0 4.1 Farmacotherapeutisch Kompas; Inleidende Tekst Antipsychotica (dutch)
  5. ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  6. ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  7. ↑ Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
  8. ↑ Kim SW et al. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.. Hum Psychopharmacol. 2009 Oct;24(7):565-73.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Retrieved from "https://wiki.psychiatrienet.nl/w/index.php?title=Haloperidol-Risperidone_LA&oldid=4148"